JON S. SAXE - 09 Sep 2025 Form 4 Insider Report for Vistagen Therapeutics, Inc. (VTGN)

Role
Director
Signature
/s/ Cynthia Anderson, Attorney-in-Fact
Issuer symbol
VTGN
Transactions as of
09 Sep 2025
Transactions value $
$0
Form type
4
Filing time
11 Sep 2025, 18:15:40 UTC
Previous filing
10 Sep 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SAXE JON S Director C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE, SOUTH SAN FRANCISCO /s/ Cynthia Anderson, Attorney-in-Fact 11 Sep 2025 0001114914

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VTGN Non-Qualified Stock Option (right to buy) Award $0 +17.6K $0.00 17.6K 09 Sep 2025 Common Stock 17.6K $3.61 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant.